VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics

Cell Rep. 2012 Mar 29;1(3):191-9. doi: 10.1016/j.celrep.2012.01.005. Epub 2012 Feb 23.

Abstract

Tumor expression of the lymphangiogenic factor VEGF-C is correlated with metastasis and poor prognosis, and although VEGF-C enhances transport to the draining lymph node (dLN) and antigen exposure to the adaptive immune system, its role in tumor immunity remains unexplored. Here, we demonstrate that VEGF-C promotes immune tolerance in murine melanoma. In B16 F10 melanomas expressing a foreign antigen (OVA), VEGF-C protected tumors against preexisting antitumor immunity and promoted local deletion of OVA-specific CD8(+) T cells. Naive OVA-specific CD8(+) T cells, transferred into tumor-bearing mice, were dysfunctionally activated and apoptotic. Lymphatic endothelial cells (LECs) in dLNs cross-presented OVA, and naive LECs scavenge and cross-present OVA in vitro. Cross-presenting LECs drove the proliferation and apoptosis of OVA-specific CD8(+) T cells ex vivo. Our findings introduce a tumor-promoting role for lymphatics in the tumor and dLN and suggest that lymphatic endothelium in the local microenvironment may be a target for immunomodulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen Presentation / immunology
  • Antigens, Neoplasm / immunology*
  • Apoptosis / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / immunology
  • Cross-Priming / immunology*
  • Dendritic Cells / immunology
  • Endothelial Cells / metabolism
  • Histocompatibility Antigens Class I / immunology
  • Immune Tolerance / immunology*
  • Lymph Nodes / immunology*
  • Lymph Nodes / pathology
  • Lymphangiogenesis
  • Melanoma, Experimental / immunology*
  • Melanoma, Experimental / pathology
  • Melanoma, Experimental / prevention & control
  • Mice
  • Neoplasm Metastasis
  • Peptides / immunology
  • Stromal Cells / metabolism
  • Vascular Endothelial Growth Factor C / metabolism*

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Histocompatibility Antigens Class I
  • Peptides
  • Vascular Endothelial Growth Factor C